2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2021-006511-29-DE
(EUCTR)		29/08/202213/06/2022A Phase 2 study of PTC587 in patients with Amyotrophic Lateral SclerosisA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) - CARDINALS Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: PTC857 oral solution
Product Code: PTC857
INN or Proposed INN: PTC857
Other descriptive name: PTC857		PTC Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		258Phase 2United States;Czechia;Spain;Ireland;Italy;France;Mexico;Argentina;Belgium;Brazil;Poland;Australia;Norway;Germany;Netherlands;Japan;Korea, Republic of;Sweden
2NCT05349721
(ClinicalTrials.gov)		May 15, 202221/4/2022Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)Amyotrophic Lateral SclerosisDrug: PTC857;Drug: PlaceboPTC TherapeuticsNULLRecruiting18 Years80 YearsAll258Phase 2United States